BlueStone Venture Partners

BlueStone Venture Partners is a life science venture capital fund investing in entrepreneurial companies. The fund provides strategic capital and support to early-stage life science companies, primarily in Series A and Series B equity rounds. It focuses on medical devices, health IT, advanced materials, and molecular diagnostics. Mara Aspinall and Thomas Nickoloff launched the venture capital fund in Tucson, Arizona in 2018.

Mara Aspinall

Managing Director

Andrew More

Director

8 past transactions

Elucid

Series B in 2022
Based in the Boston biotech and medtech hub, Elucid Bioimaging is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, vascuCAP, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from a single CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services.

Akadeum Life Sciences

Series B in 2021
Akadeum Life Sciences is working on the problem of isolating mammalian and bacterial cells from complex mixtures. It creates the simplest bioseparation products and fundamentally change the way that isolating cells and other biological targets approached. The company currently uses microbubbles for applications in cell separation and other related areas. Akadeum Life Sciences was founded in 2014 and is headquartered in Ann Arbor, Michigan, United States.

Elucid

Series A in 2021
Based in the Boston biotech and medtech hub, Elucid Bioimaging is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, vascuCAP, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from a single CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services.

GT Medical Technologies

Series B in 2020
GT Medical Technologies, Inc. develops and manufactures a medical equipment for the treatment of brain tumors. The company offers GammaTile, a biocompatible device that combines conformable collagen matrix with brachytherapy (radiation) seeds. The company caters to the healthcare industry. GT Medical Technologies, Inc. was formerly known as Gammatile, Inc. The company was founded in 2017 and is based in Tempe, Arizona.

Pyx Health

Series A in 2020
Pyx Health is a mobile solution that reduces loneliness and social isolation. It connects members outside of the traditional care setting. By providing critical and timely interventions and addressing social determinants of health, it takes care of the members when they are most vulnerable, especially after a transition of care. Pyx Health offers Pyxir, an endearing chatbot personality that walks alongside your members in their health care journey. Affectionately referred to as ‘he’ by our members, Pyxir promotes healthy interaction within the app by building trusted companionship with its members 24/7. It was founded in 2017 and is headquartered in Tucson, Arizona.

Paradigm Diagnostics

Series B in 2019
Paradigm Diagnostics specializes in advanced cancer diagnostics and biomarker-driven clinical trials, aiming to enhance treatment options for cancer patients. Utilizing next-generation sequencing and comprehensive biomarker analysis, Paradigm assesses the genomic and proteomic characteristics of individual tumors. This information allows for a detailed understanding of the specific cancer pathways involved and the potential therapies tailored to each patient's unique tumor profile. By focusing on personalized medicine, Paradigm empowers healthcare providers to offer targeted treatment strategies, ultimately improving patient outcomes in cancer care.

GT Medical Technologies

Series A in 2019
GT Medical Technologies, Inc. develops and manufactures a medical equipment for the treatment of brain tumors. The company offers GammaTile, a biocompatible device that combines conformable collagen matrix with brachytherapy (radiation) seeds. The company caters to the healthcare industry. GT Medical Technologies, Inc. was formerly known as Gammatile, Inc. The company was founded in 2017 and is based in Tempe, Arizona.
BroadSpot Imaging Corporation is developing a suite of diagnostic medical devices for eye care. They leverage advanced imaging technologies and small-scale, cloud-connected electronics to replace bulky, expensive diagnostic instruments with cost-effective handheld instruments and a series of valuable services. their technologies will fundamentally improve how eye care is delivered worldwide: eye doctors can see patients more efficiently, for less money, and more patients will gain access to high quality diagnostics as the population ages.